Dataset Information


Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration.

ABSTRACT: Dickkopf-1 is an inhibitor of Wnt signaling, which is crucial for osteoblast differentiation. We evaluated serum levels of Dickkopf-1 in 66 patients with thalassemia-induced osteoporosis who received therapy with zoledronic acid in a placebo-controlled, randomized trial. At baseline, thalassemia patients had increased serum levels of Dickkopf-1 that correlated with reduced bone mineral density of the lumbar spine and the distal radius. High Dickkopf-1 also correlated with increased bone resorption and reduced bone formation markers. Zoledronic acid produced a reduction in serum Dickkopf-1, which was associated with bone mineral density increase after 12 months of therapy. On the contrary, placebo group showed a borderline increase of Dickkopf-1, which was higher in patients who showed deterioration in pain scores. These results suggest that Dickkopf-1 is implicated in the pathogenesis of osteoporosis in thalassemia and reveal Dickkopf-1 as a possible target for the development of novel agents for the management of thalassemia-induced osteoporosis.

PROVIDER: S-EPMC2675686 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC6234378 | BioStudies
| S-EPMC7748343 | BioStudies
| S-EPMC8048549 | BioStudies
| S-EPMC4971333 | BioStudies
| S-EPMC5948273 | BioStudies
| S-EPMC4843134 | BioStudies
| S-EPMC7657394 | BioStudies
| S-EPMC3427916 | BioStudies
| S-EPMC5101059 | BioStudies
| S-EPMC3979025 | BioStudies